| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2015-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2a8a49b63eba33d252c48165fff109c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9af1ebc74a3ea81f6433e4bc75a70af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26a76127b1f2599681e8bf2eb7bbb9cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32757e57ca8ec79da8db0aa3a260bb68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c692e4a150d7edb43a05219ad68ef22a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08c538ee9cdab60af621e175206c0d2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe069f4f884731ffbab5d2a71c52d070
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82ffaa0e7f9948e5a68edd45114cf274 |
| publicationDate |
2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170035945-A |
| titleOfInvention |
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
| abstract |
The invention provides an antibody or antigen-binding portion thereof that specifically binds human CD40; PD-L1 antibody; And optionally a third component comprising a cytokine inhibitor as an active ingredient. ≪ RTI ID = 0.0 > [0002] < / RTI > |
| priorityDate |
2014-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |